New York, USA – November 1, 2021 – Acroscell, the electrophysiology platform of Creative Bioarray, provides a variety of standard and customized drug safety and pharmacological tests, as well as panel combinations for drug screening and analysis. The professional team has extensive drug discovery capabilities, expertise and mature experience, and is able to successfully meet various project goals. The experiments conducted by Acroscell provide insights into the understanding of new therapies and disease mechanisms and satisfy the various needs of customers in electrophysiological analysis.
Recently, Acroscell announced the release of its cardiac ion channel screen panels to support identifying drug interaction. Cardiovascular complications caused by drugs limit the use of many successful clinical treatments such as anti-cancer therapies. Cardiovascular complications caused by most drugs include obvious cardiac dysfunction and some negative effects such as hypertension, ischemia and arrhythmia.
One of the most important cardiovascular (CVS) burdens in safety pharmacology is a life-threatening disease called torsade de pointes (TdP), which is mainly caused by changes in the activity of hERG (Kv11.1) channels and other important cardiac ions Mediation channels (Cav1.2, Nav1.5, Kv4.3, Kir2.1 and Kv7.1). Many compounds can affect the activity of ion channels or transporters, thus having the potential to delay ventricular repolarization and lead to prolonged QT intervals.
Creative Bioarray has a group of experts with many years of experience in ion channel safety analysis and cardiotoxicity assessment, and provides electrophysiological services for in vitro (such as hERG safety) analysis and in vivo (such as ECG QT analysis) analysis. Currently, Creative Bioarray has developed a GLP-compliant in vitro electrophysiological service, providing customers with a powerful ion channel platform for characterizing the mechanism of action and safety of lead compounds. This in vitro cardiac profile screening provides a comprehensive safety analysis, including inhibition testing and IC indicators.
By evaluating its ability to block hERG channels in vitro and prolong the QTc interval of ventricular repolarization and ECG, it effectively eliminated the risk of approving drugs that may produce TdP in patients. With traditional patch clamp and MEA technology, Creative Bioarray can provide services to detect and analyze the effects of drug candidates on key cardiac ion channels and pathways, and provide predictable and repeatable data.
Creative Bioarray now provides a cardiac safety panel test to determine the interaction of the drug with the cardiac ion channel that is the target of QT prolongation. The cardiac ion channel panel can help minimize the unnecessary classification of promising compounds.
“Creative Bioarray currently provides manual patch clamp detection, using acutely isolated animal cardiomyocytes or HEK 293-Cav 1.2 cell line to test the inhibition or enhancement of the Cav1.2 channel by drugs.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “For cardiac ion channel disease research, we also provide other types of ion channel test boards. We can also provide customized solutions to satisfy diverse needs.”
About Acroscell
As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerate drug development and improve research quality for worldwide projects.
Media ContactCompany Name: Creative BioarrayContact Person: Hannah ColeEmail: Send EmailPhone: 1-631-386-8241Country: United StatesWebsite: https://acroscell.creative-bioarray.com
